Compare Alphabet Inc Class A (GOOGL) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alphabet Inc Class A vs Incyte Corporation — how do they compare? Alphabet Inc Class A trades at $351.71 (market cap $4.24T), while Incyte Corporation trades at $112.79 (market cap $22.85B). The key difference: Alphabet Inc Class A is far larger — about 185.6× Incyte Corporation's market cap, and Alphabet Inc Class A pays a 0.25% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Alphabet Inc Class A for 85 Days and Incyte Corporation for 33 Days on average.
| GOOGL | INCY | |
|---|---|---|
Market Cap | $4.24T | $22.85B |
Volume | 23,392,850 | 1,927,029 |
Sector | Media | Health |
52-Week High | $402.62 | $129.93 |
52-Week Low | $236.59 | $83.80 |
Typical Hold Time | 85 Days | 33 Days |
Enterprise Value | $4.13T | $18.35B |
Dividend Yield | 0.25% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alphabet (GOOGL) trades at $351.66, up 0.33% with strong bullish technical signals from moving averages. The company demonstrates robust fundamentals with revenue growth from $350.0B in 2024 to $402.8B in 2025 and net income surging to $132.2B. Recent earnings beats and a 86.75% analyst buy rating support positive sentiment, while YouTube's subscription price increase and AI partnerships with Anthropic and Intel highlight growth initiatives.
GOOGL presents a compelling investment case with 72 buy ratings and a $431.83 consensus price target offering 23% upside. Strong cash flow generation ($164.7B operating cash flow in 2025) and AI leadership position the stock for continued growth, though antitrust scrutiny and market volatility remain key risks requiring monitoring.
Incyte (INCY) trades at $112.79, down 0.57% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with 2025 revenue of $5.14B and net income of $1.29B, yielding robust profit margins of 92.62% gross and 27.71% net. Recent FDA approval for Atebrioz and pipeline expansion beyond JAKAFI highlight growth initiatives. Valuation metrics appear reasonable with P/E of 14.36 and P/S of 3.98, below sector averages in some cases.
The outlook remains positive with analyst consensus price target of $132.43 implying 17% upside, though near-term pressure exists from Q3 2026 expected EPS loss. Key risks include JAKAFI patent expiration post-2029 and execution on $4B sales target. Institutional sentiment leans bullish with 52% buy ratings, supporting the growth transition story despite technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
